Serlopitant
From Infogalactic: the planetary knowledge core
![]() |
|
Systematic (IUPAC) name | |
---|---|
3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(Trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)-octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one
|
|
Clinical data | |
Routes of administration |
Oral |
Identifiers | |
CAS Number | 860642-69-9 |
ATC code | none |
PubChem | CID: 23653789 |
ChemSpider | 24686685 |
UNII | 277V92K32B ![]() |
KEGG | D09378 |
ChEMBL | CHEMBL447955 |
Chemical data | |
Formula | C29H28F7NO2 |
Molecular mass | 555.527 g/mol |
|
|
|
Serlopitant (VPD-737) is a drug which acts as an NK1 receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development.[1][2]
See also
References
- ↑ Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol. 2010 Aug;184(2):616-22. doi: 10.1016/j.juro.2010.03.147 PMID 20639026
- ↑ Payton S. Urinary incontinence: Neurokinin receptor antagonist inferior to tolterodine for OAB. Nature Reviews Urology 2010; 7:418. doi:10.1038/nrurol.2010.105
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- NK1 receptor antagonists
- Pharmacology stubs